Mometasone Furoate
Rank #480 of 500 drugs by total cost
Data: CMS Medicare Part D, 2023 (most current available) · Updated March 2026
$14.7M
Total Cost
266,966
Total Claims
$14.7M
Total Cost
8,842
Prescribers
$55
Cost per Claim
118,010
Beneficiaries
313,377
30-Day Fills
$1,659
Avg Cost/Provider
30
Avg Claims/Provider
Share of Medicare Part D Spending
0.01%
of total Medicare Part D spending
$14.7M of $275.65B
Top Prescribers by Cost
Top 10 prescribers of $14.7M total
Top Prescribers of Mometasone Furoate
| # | Provider | Specialty | Location | Claims | Cost |
|---|---|---|---|---|---|
| 1 | Xiangsheng Zheng | Internal Medicine | Birmingham, AL | 1,505 | $187K |
| 2 | Xiaoqin Yin | Family Practice | Flushing, NY | 882 | $120K |
| 3 | Hung Dang | Family Practice | Arlington, TX | 354 | $96K |
| 4 | Guozi Weng | Nurse Practitioner | New York, NY | 441 | $51K |
| 5 | Xiandong Shi | Internal Medicine | Flushing, NY | 354 | $41K |
| 6 | Steven Kong | Physician Assistant | Brooklyn, NY | 370 | $39K |
| 7 | Victoria Sepesky | Interventional Pain Management | Monessen, PA | 212 | $38K |
| 8 | Juan Candelario Lanza | Pulmonary Disease | Caguas, PR | 152 | $38K |
| 9 | John Fritz | Family Practice | Jersey City, NJ | 351 | $35K |
| 10 | Thomas Tarin | Otolaryngology | Merrillville, IN | 352 | $33K |
| 11 | Ritesh Kalra | Internal Medicine | Fair Lawn, NJ | 129 | $31K |
| 12 | Singmay Siu | Internal Medicine | Brooklyn, NY | 246 | $31K |
| 13 | Abigail Harada | Allergy/ Immunology | Honolulu, HI | 113 | $28K |
| 14 | Kwangsu Kim | Podiatry | Tuckahoe, NY | 1,405 | $28K |
| 15 | Weining Liang | Internal Medicine | Flushing, NY | 210 | $28K |
Top prescribers ranked by total cost for this drug in 2023.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 477 | Lansoprazole (Lansoprazole) | $15.0M | 309,355 |
| 478 | Raloxifene Hcl (Raloxifene Hcl) | $14.8M | 198,063 |
| 479 | Lanthanum Carbonate (Lanthanum Carbonate) | $14.7M | 13,783 |
| 480 | Mometasone Furoate (Mometasone Furoate) | $14.7M | 266,966 |
| 481 | Lorlatinib (Lorbrena) | $14.7M | 720 |
| 482 | Rasagiline Mesylate (Rasagiline Mesylate) | $14.5M | 47,985 |
| 483 | Pazopanib Hcl (Votrient) | $14.5M | 1,156 |
Related Analysis
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology